Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: Diagnosis and treatment

Journal of Clinical Pathology

Volumn 54, Issue 4, 2001, Pages 272-274

  Baglin, T P ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Heparin induced thrombocytopenia; Immune complexes; Platelet aggregating factor; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR;

BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG WITHDRAWAL; HUMAN; IMMUNOASSAY; LABORATORY TEST; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; PIPECOLIC ACIDS; PLATELET COUNT; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0035057203     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.4.272     Document Type: Review

References (32)

1. Heparin-induced thrombocytopenia
2. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome
3. Heparin-associated thrombocytopenia
4. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations
5. Heparin-induced thrombocytopenia
6. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
7. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
8. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients
9. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
10. Immune endothelialcell injury in heparin-associated thrombocytopenia
11. Heparin-induced thrombocytopenia: New insights into the impact of the FcgammaRIIa-R-H131 polymorphism
12. Laboratory diagnosis of heparin-induced thrombocytopenia
13. FcgRIIA allotype does not influence platelet aggregation in response to HIT sera
14. Laboratory tests for heparin-induced thrombocytopenia: A multicenter study
15. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia
16. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin induced platelet activation test and platelet factor 4/heparin enzyme-linked immunosorbent assay
17. Platelet pre-activation is not a primary mechanism for platelet activation in HIT
18. Diagnostic test for heparin-induced thrombocytopenia: Detection of platelet microparticles using flow cytometry
19. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia
20. A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT)
21. His131 receptor
22. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia
23. Frequency of heparin platelet factor 4 antibodies in patients receiving heparin
24. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
25. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia
26. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome
27. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (ORG 10172)
28. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia
29. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
30. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
31. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT
32. Synthesis of thrombin-inhibiting heparin mimetics without side effects